Dose-dependent association between bisphosphonates and jaw complications
This article has no abstract so we have provided the first paragraph of the full text.
Bisphosphonates successfully treat bone metastases associated with certain cancers and bone loss caused by androgen deprivation therapy for prostate cancer, but bisphosphonate use has been associated with osteonecrosis of the jaw. Wilkinson et al. surveyed data from the Medicare-linked Surveillance, Epidemiology and End Results (SEER) database to investigate this association. The authors identified 14,349 cancer patients who were treated with intravenous pamidronate or zoledronic acid; these patients were matched with 28,698 cancer patients who did not receive bisphosphonates.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.